Clinical Trial Update: Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing talabostat plus docetaxel to docetaxel alone in patients with stage IIIB/IV non-small cell lung cancer after platinum therapy was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Talabostat (talabostat)

Snippet

Sponsor: Point Therapeutics | Conditions: Carcinoma, Non-Small Cell Lung | Phase 3 | Status: TERMINATED